What is the generic name?

BELIMUMAB

What is the Trade Name for BELIMUMAB?

BENLYSTA

What are the Indications for BELIMUMAB?

• 1 INDICATIONS AND USAGE BENLYSTA (belimumab) is indicated for the treatment of: ‚Ä¢ patients aged 5 years and older with active, autoantibody ‚Äë positive systemic lupus erythematosus (SLE) who are receiving standard therapy, and ‚Ä¢ adult patients with active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics. Use of BENLYSTA is not recommended in these situations. BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: ‚Ä¢ patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy; ( 1 ) ‚Ä¢ adult patients with active lupus nephritis who are receiving standard therapy. ( 1 ) ‚Ä¢ Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics. Use of BENLYSTA is not recommended in these situations. ( 1 )

References: https://open.fda.gov/